 "Pharma Stocks, Sun Pharma, Cadila, Cipla")
Shares of Sun Pharmaceutical Industries were trading 2% higher at Rs 587 per share on the BSE in an otherwise subdued market, nearing their 52-week high of Rs 609 per share touched on February 12, 2018.
The pharmaceutical stock which is quoting at its highest level since February 15, 2018, has rallied 32% in past five weeks as compared to 3% rise in the S&P BSE Sensex.
Since May 25, post its January-March (Q4FY18) results, Sun Pharma outperformed the market by surging 25% on expectation of revenue growth on the back of three speciality drug launches in US
The pharmaceutical stock which is quoting at its highest level since February 15, 2018, has rallied 32% in past five weeks as compared to 3% rise in the S&P BSE Sensex.
Since May 25, post its January-March (Q4FY18) results, Sun Pharma outperformed the market by surging 25% on expectation of revenue growth on the back of three speciality drug launches in US
